REVB Revelation Biosciences, Inc. - Common Stock
$1.02
Price · May 20, 2026
Fundamentals as of May 7, 2026
52W Range
$0–$8
7% of range
Analyst Rating
BUY
7 analysts
Price Target
$19
+1787% upside
P/E (TTM)
—
ROE
—
Net Profit Margin
—
REVB Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$1.02
Market Cap
—
P/E (TTM)
—
EPS (TTM)
—
Revenue (TTM)
—
Div Yield
—
ROE
—
Debt/Equity
—
52W Range
$0 – $8
REVB Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
—
EPS
—
Free Cash Flow
—
Margins
—
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
REVB
Peer Median
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
REVB
Peer Median
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
REVB
Peer Median
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
REVB
Peer Median
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
REVB
Peer Median
REVB Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
BUY
7 analysts
- Strong Buy 2 28.6%
- Buy 4 57.1%
- Hold 1 14.3%
- Sell 0 0.0%
- Strong Sell 0 0.0%
12-Month Price Target
2 analysts · 2026-05-16
Median
$19.25
← Below all targets
$1.02
Low
$16.00
High
$22.50
Median target
$19.25
+1787.3%
Mean target
$19.25
+1787.3%
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
5.1%
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| March 31, 2026 | $-2.71 | $-1.17 | -1.5% |
| Dec. 31, 2025 | $-23.95 | $-3.73 | -20.2% |
| Sept. 30, 2025 | $-7.08 | $-5.45 | -1.6% |
| June 30, 2025 | $-28.04 | $-18.18 | -9.9% |
| March 31, 2025 | $-25.32 | $-84.21 | 58.9% |
Peer Comparison Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| REVB | — | — | — | — | — | — |
| AKTX | $26.17B | — | — | — | -64.1% | — |
| CDIO | — | — | — | — | — | — |
| BRTX | $10M | -0.7 | -10.3% | -3959.4% | -547.6% | 93.4% |
| GRI | $122.9K | -0.0 | — | — | -256.3% | — |
| ALZN | $5M | -0.5 | — | — | -121.7% | — |
| SHPH | $4M | -0.3 | 0.00% | — | -400.1% | — |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement 12
| Metric | Trend | Q1 2026 | Q2 2024 |
|---|---|---|---|
| R&D Expense | $1M | $1M | |
| SG&A Expense | $2M | $1M | |
| Operating Expenses | $3M | $3M | |
| Operating Income | $-3M | $-3M | |
| Other Non-op | $83.4K | $-6M | |
| Income Tax | · | $0 | |
| Net Income | $-3M | $-8M | |
| EPS (Basic) | $-2.71 | $-5.13 | |
| EPS (Diluted) | $-2.71 | $-5.13 | |
| Shares (Basic) | 3,207,720 | 1,635,234 | |
| Shares (Diluted) | 3,207,720 | 1,635,234 | |
| EBITDA | $-3M | $-3M |
Balance Sheet 19
| Metric | Trend | Q1 2026 | Q2 2024 |
|---|---|---|---|
| Cash & Equivalents | $14M | $12M | |
| Prepaid Expense | $92.6K | $125.7K | |
| Current Assets | $14M | $12M | |
| PP&E (Net) | $140.7K | $70.8K | |
| PP&E (Gross) | $246.9K | $151.1K | |
| Accum. Depreciation | $106.2K | $80.4K | |
| Other Non-current Assets | $30.9K | · | |
| Total Assets | $15M | $12M | |
| Accounts Payable | $828.2K | $1M | |
| Accrued Liabilities | $468.1K | $8M | |
| Current Liabilities | $1M | $11M | |
| Capital Leases | $638.2K | · | |
| Total Liabilities | $2M | $11M | |
| Common Stock | $3.9K | $1.6K | |
| Paid-in Capital | $65M | $38M | |
| Retained Earnings | $-52M | $-37M | |
| Stockholders' Equity | $13M | $1M | |
| Liabilities + Equity | $15M | $12M | |
| Shares Outstanding | 3,908,420 | 1,643,395 |
Cash Flow 6
| Metric | Trend | Q1 2026 | Q2 2024 |
|---|---|---|---|
| Stock-based Comp | $471.0K | · | |
| Operating Cash Flow | $-3M | · | |
| CapEx | $71.9K | · | |
| Investing Cash Flow | $-71.9K | · | |
| Financing Cash Flow | $7M | · | |
| Free Cash Flow | $-3M | · |
Profitability 2
| Metric | Trend | Q1 2026 | Q2 2024 |
|---|---|---|---|
| ROA | -31.6% | -59.3% | |
| ROE | -37.9% | -133.7% |
Liquidity & Solvency 2
| Metric | Trend | Q1 2026 | Q2 2024 |
|---|---|---|---|
| Current Ratio | 10.0 | 1.1 | |
| Quick Ratio | 10.0 | 1.1 |
Valuation (TTM) 8
| Metric | Trend | Q1 2026 | Q2 2024 |
|---|---|---|---|
| Net Income TTM | $-9M | $-15M | |
| Market Cap | $5M | $151M | |
| P/E | -0.0 | -0.3 | |
| P/B | 0.4 | 132.1 | |
| P / Tangible Book | 0.4 | 132.1 | |
| P / Cash Flow | -1.5 | · | |
| P / FCF | -1.4 | · | |
| Earnings Yield | -3069.2% | -328.8% |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.